Navigation Links
ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
Date:2/28/2017

ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of novel pharmaceuticals for the treatment of chronic diseases, has announced Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. With more than 15 years of clinical development experience with a number of multinational drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, President, to continue advancing the company’s lead drug candidate, AC0010. The drug candidate is currently in clinical trials for the treatment of non-small cell lung cancer (NSCLC) in both China and the US. A pyrrolopyrimidine-based irreversible inhibitor of the EGFR tyrosine kinase, AC0010 provides NSCLC patients with a new treatment alternative should first generation EGFR tyrosine kinase inhibitors fail to produce a durable response. Thus far, AC0010 has demonstrated efficacy, tolerability, and safety in clinical trials in both China and the U.S. Global clinical trials are slated for late 2017.

Before joining ACEA, Dr. Luo was Compound Development Team Lead, and Senior Leadership Member of Exploratory Medicine and Early Development at Johnson & Johnson (JNJ). Prior to JNJ, he was the Sr. Director of Early Clinical Development at Daiichi-Sankyo, and Head of the Tumor Pharmacology Group at Bristol-Myers Squibb. In total, Dr. Luo has participated in more than 20 oncology drug development trials around the globe, and has particular expertise in lung cancer therapeutics. “We are thrilled to have Roger join ACEA at this critical phase of the company’s history,” said Xiao Xu. “Roger’s experience and proficiency in drug development will be a major asset as we usher AC0010 through clinical trials.”

For more information about ACEA Biosciences, click here.

For further information please contact:                                                                                    
ACEA Biosciences, Inc.                                                                                                                
Dr. Jeff Xue                                                                                                                                    
Phone: +1 858 724 0928 x 3075                                                                                                
email: jxue(at)aceabio(dot)com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14105641.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. Northstar Biosciences Launches All Natural Skincare Solutions
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
7. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
8. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- On Thursday, March 23, 2017, the ... 0.07%; the Dow Jones Industrial Average edged 0.02% lower, ... at 2,345.96, marginally dropping 0.11%. US markets saw a ... sectors finished in red, and 1 sector ended flat ... coverage on the following Biotechnology equities: BioDelivery Sciences International ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):